Plain-English translation of NCT06215989 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether colchicine, a cheap anti-inflammatory medication, can help prevent serious heart problems after you've had a heart attack or acute coronary syndrome. Even though doctors give patients the best available treatments after a heart attack, some people still suffer another heart attack or other dangerous heart events. Researchers want to see if this medication, started early, might reduce inflammation in the heart and help protect you from these complications.
After a heart attack, inflammation in the blood vessels can lead to more heart problems and even death. Recent heart disease guidelines recommend this medication for certain patients, but doctors still need to prove whether starting it right after a heart attack—rather than waiting—gives people greater protection.
You likely qualify if…
You likely don't qualify if…
Within 48 hours of your heart attack diagnosis, you would be randomly assigned to receive either the active medication or a placebo pill. You would take one tablet daily for 12 months while continuing your standard heart attack treatments. The research team would follow up with you throughout the year to monitor your health and watch for any heart-related events. At the end of one year, they would evaluate whether this medication helped reduce your risk of future heart problems.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Sponsor
Beijing Anzhen Hospital
Enrollment target
~6,574 participants
Started
September 2024
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yujie Zhou, PhD, MD
Beijing Anzhen Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.